What is TNF Pharmaceuticals Forward Dividend Yield %?
As of today (2025-05-05), the Forward Annual Dividend Yield of TNF Pharmaceuticals is 0.00%.
As of today (2025-05-05), the Trailing Annual Dividend Yield of TNF Pharmaceuticals is 0.00%.
TNFA's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.535 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of TNF Pharmaceuticals's Forward Dividend Yield %
For the Biotechnology subindustry, TNF Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TNF Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TNF Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where TNF Pharmaceuticals's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
TNF Pharmaceuticals Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of TNF Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNFA has been successfully added to your